# A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

> **NCT06064890** · PHASE1,PHASE2 · RECRUITING · sponsor: **AviadoBio Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Frontotemporal Dementia
- FTD
- FTD-GRN
- Dementia, Frontotemporal

## Interventions

- **PROCEDURE:** Intrathalamic AAV.PGRN administration
- **GENETIC:** Intrathalamic AVB-101

## Key facts

- **NCT ID:** NCT06064890
- **Lead sponsor:** AviadoBio Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-30
- **Primary completion:** 2026-04-01
- **Final completion:** 2030-03-21
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06064890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06064890, "A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06064890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*